The annual EURORDIS Photo Award contest is inviting people worldwide to visually express what life is like with a rare disease, while raising awareness through their work of these disorders. Submissions for next year’s awards are open until Jan. 31. The competition is organized by France-based EURODIS, an alliance…
News
Growth hormone (GH) therapy initiated at an earlier age and sustained for a longer period results in greater improvements in growth and body composition in children with Prader-Willi syndrome (PWS), according to data from a real-world study. These findings further support the current practice of starting GH treatment as…
A three-week program based on Mediterranean diet and exercise, and performed three times in six years, led to significant weight loss and reduced cholesterol levels in adults with Prader-Willi syndrome (PWS), an Italian study reports. The study, “Changes of Body Weight and Body Composition in Obese…
To empower and equip members of the rare disease community to engage state leaders in matters of importance to patients and their families, the National Organization for Rare Disorders (NORD) has launched an initiative across the U.S. Its goal is to establish a Rare Disease Advisory Council (RDAC)…
The frequency of skin picking and anxiety in people with Prader-Willi syndrome (PWS) depends on their specific type of genetic defects, an eight-year study found. Treatment with growth hormone (GH) therapy increased the prevalence of anxiety to a different extent in specific genetic groups, the data showed. The study,…
The Prader-Willi Syndrome Association (PWSA) USA, a nonprofit organization that supports education, advocacy, and awareness for those with the complex genetic disorder, announced that it will hold its first benefit concert, “Hope for the Holidays,” on Sunday, Dec. 13, at 7:30 p.m. EST. The free, virtual event — designed…
The first wave of COVID-19 in Europe severely disrupted access to care and raised stress and anxiety in people with rare diseases, negatively affecting their health and well-being, according to a survey conducted by Eurordis-Rare Diseases Europe. “People living with rare diseases in Europe have found themselves caught as collateral…
The maternal SMCHD1 protein ensures genomic imprinting and the effective silencing of particular genes by protecting them from “gene-activating” proteins in the fertilized egg cell (or oocyte), according to a study in mice. Since SMCHD1’s gene silencing effects are known to contribute to Prader-Willi syndrome (PWS), these findings may help…
A Phase 2 clinical trial testing pitolisant as a treatment for excessive daytime sleepiness (EDS) in Prader-Willi syndrome (PWS) has started recruiting patients at its Texas site and is activating nine other study sites across the U.S. Harmony Biosciences expects the…
Leaders in the U.S. rare disease community came together recently for a webinar to present helpful information on how to start a nonprofit and patient registry. They shared about how their respective organizations came to be, as well as the benefits of creating patient registries and how they can help…
Recent Posts
- Safety concerns over PWS therapy ARD-101 pause global clinical trial
- Starting growth hormone before age 2 does not harm PWS sleep
- I’m hopeful a new treatment will benefit my son with Prader-Willi syndrome
- Palatin to test 2 obesity-targeting drugs for PWS in clinical trials this year
- Still-recruiting ARD-101 trial for PWS lowers US enrollment age to 7
- For rare disease families, February is a month of both love and awareness
- Muscle, bone signaling imbalances found in non-obese PWS children
- Most PWS patients meet nutrient targets but struggle with calorie control
- Adults with PWS need lifelong support in daily activities, study finds
- Celebrating a milestone in life with Prader-Willi syndrome